Inspire Investing LLC Grows Position in Insulet Corporation $PODD

Key Points

• Inspire Investing LLC increased its stake in Insulet Corporation (NASDAQ:PODD) by 299.5% during the first quarter, acquiring an additional 3,088 shares for a total value of $1,082,000.
• Several hedge funds, including Acadian Asset Management LLC and Strs Ohio, also significantly increased their holdings in Insulet, highlighting heightened investor interest in the company.
• Insulet's recent quarterly earnings exceeded expectations, reporting $1.17 EPS against a consensus estimate of $0.92, alongside a 32.9% year-over-year revenue increase.

Inspire Investing LLC grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 299.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,119 shares of the medical instruments supplier's stock after purchasing an additional 3,088 shares during the quarter. Inspire Investing LLC's holdings in Insulet were worth $1,082,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. lifted its stake in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares during the period. Groupama Asset Managment lifted its stake in Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after acquiring an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after acquiring an additional 27,408 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Insulet by 27,298.6% in the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after acquiring an additional 661,717 shares during the period.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Stock Down 2.4%

Shares of NASDAQ:PODD traded down $8.16 on Tuesday, hitting $332.13. 812,055 shares of the company traded hands, compared to its average volume of 747,317. Insulet Corporation has a 52 week low of $225.37 and a 52 week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a 50 day simple moving average of $312.38 and a 200-day simple moving average of $292.79. The company has a market cap of $23.38 billion, a PE ratio of 100.95, a PEG ratio of 2.84 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the company earned $0.55 earnings per share. The company's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays raised their price target on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.